Acelyrin Inc.
- Address
- 4149 Liberty Canyon Road
Sponsor Overview
Specializations
Rheumatologic and Autoimmune Disease Research
Acelyrin Inc. demonstrates a concentrated focus on developing therapeutic interventions for rheumatologic conditions and autoimmune disorders. The company's research portfolio emphasizes conditions characterized by chronic inflammation and immune system dysregulation affecting connective tissues and joints.
- Rheumatoid Arthritis
- Axial Spondyloarthritis
- Hidradenitis Suppurativa
The therapeutic development programs target inflammatory pathways implicated in these debilitating conditions, with particular attention to diseases that significantly impact patient mobility and quality of life through progressive joint damage and systemic inflammation.
Dermatologic Inflammatory Conditions
The organization maintains active research initiatives in chronic inflammatory skin disorders, specifically addressing conditions that involve complex immune-mediated mechanisms affecting cutaneous and subcutaneous tissues. This research area reflects an understanding of the intersection between dermatology and immunology.
- Chronic Suppurative Skin Conditions
- Immune-Mediated Dermatoses
The company's interest in hidradenitis suppurativa represents engagement with a challenging dermatologic condition characterized by recurrent painful nodules and abscesses, demonstrating commitment to addressing unmet needs in inflammatory skin disease management.
Musculoskeletal Immune Disorders
Acelyrin Inc. pursues research in spondyloarthropathies and related musculoskeletal inflammatory conditions. The focus encompasses diseases affecting the axial skeleton, peripheral joints, and associated structures, where immune-mediated inflammation drives progressive structural damage.
- Ankylosing Spondylitis Spectrum Disorders
- Inflammatory Arthropathies
- Chronic Joint Inflammation
The research emphasis on axial spondyloarthritis highlights engagement with conditions affecting spinal mobility and function, representing a therapeutic area where innovative treatments are needed to prevent irreversible structural changes and preserve patient function.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| 22104: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Active Psoriatic Arthritis |  Bulgaria Czechia Germany Hungary Poland Spain | Not Recruiting |
| Efficacy and Safety Evaluation of Izokibep in Patients with Non-infectious Intermediate, Posterior, or Pan-uveitis: A Phase 2b Randomized Controlled Trial |  Austria Czechia France Germany Italy Spain | Not Recruiting |
| Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Izokibep Efficacy and Safety in Moderate to Severe Hidradenitis Suppurativa | France Germany Hungary Poland Spain | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 98 sites across their trial portfolio.
Therapeutic Focus
- 1.Eye Diseases1 trial138 other sponsors
- 2.Musculoskeletal Diseases1 trial238 other sponsors
- 3.Skin and Connective Tissue Diseases1 trial247 other sponsors
Partnered Research Centres
98 centres- Address
- Calle Del Marques De La Valdavia 103 Bajo Local, 28100 Alcobendas
- Address
- Ul. Swietojanska 1, 61-113 Poznan
- Address
- Via Giovanni Battista Grassi 74, 20157 Milan
- Address
- Hohenzollernring 74, Herz-Jesu, 48145 Munster
- Address
- Carrer De La Feixa Llarga S/N, 08907 L'hospitalet De Llobregat
- Address
- 28. Rijna 3348/65, Moravska Ostrava, 702 00 Moravska Ostrava A Privoz
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Acelyrin Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.